Follistatin is a naturally occurring protein that binds myostatin, utilized experimentally to drive muscle growth and recovery. Users typically run daily doses of 100 mcg, though reported protocols span a wide range from 50 mcg to 10 mg. While some users report fluid retention, other common issues like injection-site reactions or gastrointestinal distress have not been a consistent theme. The evidence base for this peptide remains thin, as all human use is off-label and the majority of exploratory indications lack posted results.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Follistatin currently holds a low evidence tier, as the existing human literature is restricted to five diagnostic and mechanistic studies rather than clinical trials for therapeutic use. While the peptide is frequently discussed in preclinical research, there are zero registered human trials and no completed studies evaluating its efficacy for specific health indications. This lack of clinical data means that current research remains entirely exploratory, with no evidence base to support its use outside of controlled laboratory settings.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Diagnostic & mechanistic studies
5 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 10 out-of-stock offers not shown
How Follistatin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No completed trial has been identified for follistatin, so no dosing figure is reliably on record for this tier.
No structured protocol details captured for this tier yet.
Most users who specified a schedule take Follistatin at 100 mcg subcutaneously each day, while a smaller group doses weekly at 5 mg and others did not state a frequency; reported amounts span from 50 mcg up to 10 mg.